DNA IVF: Three Babies Born Free of Inherited Disease
Breakthrough in Mitochondrial Donation: Early Successes Offer Hope to Families
Table of Contents
Newcastle, UK – Groundbreaking advancements in mitochondrial donation are offering renewed hope to families affected by debilitating inherited mitochondrial diseases. Early results from pioneering treatments in teh UK show that babies born following pronuclear transfer (PNT) are healthy and free from the condition, marking a meaningful milestone in reproductive medicine.
Pioneering Treatment Offers New Hope
Professor Bobby McFarland, Director of the NHS Highly Specialised Service for rare Mitochondrial Disorders at Newcastle Hospitals NHS Foundation Trust and Professor of Paediatric Mitochondrial Medicine at Newcastle University, is the first author of one of the key papers detailing these early successes. He expressed optimism about the findings, stating, “While longer term follow-up of children born following mitochondrial donation is of paramount importance, these early results are very encouraging. Seeing the joy and relief these children have brought to their parents is such a privilege.”
Professor McFarland highlighted the rigorous follow-up process in place, emphasizing its thoroughness. “We believe that the follow-up process we have put in place is thorough, since it allows us to detect and review even minor health conditions in children born after pronuclear transfer such as a urinary tract infection,” he explained.
A beacon of Hope for Affected Families
The Lily Foundation, a leading charity dedicated to combating mitochondrial disease, has been a staunch supporter of the Newcastle-based research. Liz Curtis, Lily founder and CEO, shared her elation: “We’re absolutely delighted with the results of these published papers. We fought long and hard for this change so that families could have choices. After years of waiting, we now know that eight babies have been born using this technique, all showing no signs of mito. For many affected families, it’s the first real hope of breaking the cycle of this inherited condition.”
Understanding Mitochondrial Disease and Donation
Mitochondrial disease encompasses a group of genetic conditions that impair the function of mitochondria, the energy-producing powerhouses within our cells.Pronuclear transfer (PNT) is a specialized technique designed to prevent the transmission of mitochondrial DNA (mtDNA) disease. It involves transferring the nuclear DNA from a fertilized egg of intended parents into a fertilized donor egg that has had its own faulty mitochondria removed.
Pre-implantation genetic testing (PGT) is an additional procedure that can be used to screen embryos for genetic conditions, further enhancing the chances of a healthy pregnancy.
A Global First: Legal Framework and Licensing
The UK has been at the forefront of this medical innovation. In 2015, following extensive public debate and rigorous scientific and ethical review, the UK became the first country worldwide to legalize mitochondrial donation. This landmark legislation empowered the Human Fertilisation and Embryology Authority (HFEA) to permit mitochondrial donation treatments for women at high risk of passing on serious mitochondrial DNA diseases to their children. Subsequently, Australia has also updated its laws to allow similar treatments.
The HFEA plays a crucial role in regulating and granting licenses for these procedures. In 2017, the Newcastle Fertility Center, part of Newcastle Hospitals NHS Foundation Trust, received the first license to perform clinical mitochondrial donation via pronuclear transfer. A dedicated clinical pathway was subsequently established, integrating mitochondrial clinicians within NHS England’s Highly Specialised Service.
Funding and Support
The development and implementation of the Mitochondrial Reproductive Care Pathway have been supported by the NHS at The Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH).Further crucial support was provided by Wellcome, with infrastructural assistance from Newcastle University. The initiative also benefits from a National Institute for Health and Care Research (NIHR) Biomedical Research Centre award to NUTH. The NHS Highly Specialised Services for Rare Mitochondrial Disorders receives backing from NHS England, and a career development award was granted to Dr. Hyslop by Health Education England and the NIHR.